Beijing SL Pharmaceutical Faces Declining Profitability Amid Shift in Market Outlook

Beijing SL Pharmaceutical Co., Ltd., a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation. This revision reflects a notable shift in the company's technical indicators, which have transitioned from a bullish stance to a mildly bullish outlook. Key financial metrics reveal challenges for the company. The Return on Capital Employed (ROCE) stands at a low 3.40%, indicating limited profitability relative to the total capital employed. Over the past five years, net sales have contracted at an annual rate of 14.83%, while operating profit has seen a significant decline of 171.55%. Additionally, the company has reported negative results for four consecutive quarters, with a net profit of CNY 29.41 million reflecting a decrease of 71.72%. Net sales for the same period reached CNY 458.01 million, down by 14.62%. Operating cash flow has also hit a low of CNY 120.32 million. In the past year, Beijing SL Pharmaceutical has underperformed the broader market, achieving a return of 6.06%, compared to the China Shanghai Composite's 24.03%. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.